Project Grant R41AI188793
Award Date 9/12/25
Completion Date 8/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Vast Therapeutics, Inc. The grant, effective from September 11, 2025 to August 31, 2027, will support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for difficult non-tuberculous mycobacterial lung infections. The project aims to evaluate the pharmacokinetics and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vast Therapeutics, Inc. a $2,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nitric oxide-releasing formulation (ALX1) for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients. The objective is to answer critical questions needed to initiate Phase II proof-of-concept clinical trials for this broad-spectrum antibacterial therapy,...
- This $1,498,642 Cooperative Agreement, awarded on April 22, 2025 by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), aims to compare clinical outcomes across specific biologics and identify biomarkers to predict patient response to biologic therapy for chronic rhinosinusitis with nasal polyps (CRSWNP). The study will enroll CRSWNP patients electing to pursue biologic therapy and obtain baseline data, including sinonasal mucus...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Optimeos Life Sciences, Inc., a biotechnology company in New Jersey. The grant supports the development of an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat severe immune deficiencies such as ADA-SCID. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a pharmaceutical research and development company based in Austin, Texas. The grant supports the development of an inhaled, fixed-dose combination powder product containing both azithromycin and amikacin for the treatment of non-tuberculous mycobacterial (NTM) infections. The goal is to improve...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $158,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Temple University to conduct an exploratory study on a new pH-responsive, ionizable hybrid nanocarrier for enhancing drug delivery to bacterial biofilms. The goal is to develop a nanocarrier design that can effectively deliver a range of therapeutic agents to biofilms, which are the main cause of chronic wound infections...